Search

Your search keyword '"Mariette , Xavier"' showing total 288 results

Search Constraints

Start Over You searched for: Author "Mariette , Xavier" Remove constraint Author: "Mariette , Xavier" Journal annals of the rheumatic diseases Remove constraint Journal: annals of the rheumatic diseases
288 results on '"Mariette , Xavier"'

Search Results

1. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

3. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis

4. Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritis

6. Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritis.

10. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project

12. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update

14. Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome

15. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)

18. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers

19. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögrenʼs syndrome: A consensus and data-driven methodology involving three international patient cohorts

20. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force

23. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update

25. Defining disease activity states and clinically meaningful improvement in primary Sjögrenʼs syndrome with EULAR primary Sjögrenʼs syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)

26. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study)

28. Validation of EULAR primary Sjögrenʼs syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)

29. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry

30. 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19

34. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force

35. SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases

36. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

37. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

38. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)

39. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis

41. European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance

42. EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19

43. Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial

46. Salivary gland epithelial cells from patients with Sjögren’s syndrome induce B-lymphocyte survival and activation

47. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities

49. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2

Catalog

Books, media, physical & digital resources